ReviewCurrent treatment options in oncology2020
Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions.
Review in Current treatment options in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy.PloS one · 2026Article
- [Radiologically guided interventional therapies for the treatment of neuroendocrine tumors].Radiologie (Heidelberg, Germany) · 2024Article
- Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?Seminars in interventional radiology · 2024Review
- Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.Abdominal radiology (New York) · 2022Review
- Neuroendocrine hepatic metastatic disease: the surgeon's perspective.Abdominal radiology (New York) · 2022Article
- Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications.Expert opinion on drug delivery · 2021Review
- Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementLiver-directed therapy should be considered for patients with unresectable liver metastases from neuroendocrine tumor if symptomatic or progressing despite medical management. Our experience and current literature shows that the bland embolization, chemoembolization, and radioembolization are very effective in controlling symptoms and disease burden in the liver, and that these embolization modalities are similar in terms of efficacy and radiologic response. Their safety profiles differ, however, with recent studies suggesting an increase in biliary toxicity with drug-eluting bead chemoembolization over conventional chemoembolization, and a risk of long-term hepatotoxicity with radioembolization. For this reason, we tailor the type of embolotherapy to each patient according to their clinical status, symptoms, degree of tumor burden, histologic grade, and life expectancy. We do not recommend a "one-size-fits-all" approach. Our general strategy is to use bland embolization as first-line embolotherapy, and radioembolization for patients with high-grade tumors or who have failed other embolotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.